Long-term Impact of NMDAR Encephalitis, Level 3

NMDA receptor antibody encephalitis is a rare autoimmune neurological disease of the central nervous system with an estimated incidence of 1.5 people per million per year. Patients with anti-NMDAR encephalitis experience an acute phase of the disease characterized by psychosis, memory loss, seizures, autonomic nervous system instability, or coma. Since the discovery of this disease 14 years ago by Prof. Dalmau, the clinical presentation of the acute phase has been well characterized, while the psychosocial impact of the disease remains largely unexplored. Currently, there are few cohort studies of patients that have identified persistent cognitive impairment as a factor impacting remission after the acute phase. Given the scarcity of information concerning the post-acute phase, it is therefore essential to determine the long-term social and psychological outcomes and their daily effects on the social and functional life of this severe disease. This is especially important as the patients are young, with a median age of 21 years, and may face lasting limitations potentially detrimental to their success in professional, educational, or social environments.

NCT Number	NCT07158229
Lead Sponsor	Hospices Civils de Lyon Collaborators: Charite University, Berlin, Germany
Conditions	NMDAR Autoimmune Encephalitis
Enrollment	30 participants
Start Date	2025-11-21
Primary Completion	2026-11-21 (estimated)
Study Completion	2026-11-21 (estimated)
Updated on ClinicalTrials.gov	2026-02-17